The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature

References

• LiuZWangZXiaoYLuYLuYAssociation between the interleukin-6 gene polymorphisms and renal cancer riskImmunol Lett2015164212512825766682
   PubMed Web of Science ®Google Scholar
• MiyazakiJItoKFujitaTProgression of human renal cell carcinoma via inhibition of RhoA-ROCK axis by PARG1Transl Oncol201710214215228131798
   PubMed Web of Science ®Google Scholar
• LiuZLiuXWLiuSALvJJFuQClinical significance of changes of expression of the Wnt/β-catenin signaling pathway in renal clear cell carcinomaEur Rev Med Pharmacol Sci201620234840484527981554
   PubMed Web of Science ®Google Scholar
• BazziWMTinALSjobergDDBernsteinMRussoPThe prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinomaCan J Urol20162318151815426892055
   PubMed Web of Science ®Google Scholar
• XiaYLiuLXiongYPrognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorBMC Cancer2017171708028114889
   PubMed Web of Science ®Google Scholar
• BorregalesLDAdibiMThomasAZWoodCGKaramJAThe role of neoadjuvant therapy in the management of locally advanced renal cell carcinomaTher Adv Urol20168213014127034725
   PubMedGoogle Scholar
• BarriosCHHerchenhornDChacónMCabrera-GaleanaPSajbenPZhangKSafety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinomaOnco Targets Ther20169235839584527713637
   PubMed Web of Science ®Google Scholar
• RovithiMde HaasRRHoneywellRJAlternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growthJ Exp Clin Cancer Res201635113814927604186
   PubMed Web of Science ®Google Scholar
• ChangWSLiaoCHMiaoCEThe role of functional polymorphisms of cyclooxygenase 2 in renal cell carcinomaAnticancer Res201434105481548625275044
   PubMed Web of Science ®Google Scholar
• KimSHSeoSILeeHMA prospective multicenter trial of the efficacy and tolerability of neoadjuvant sunitinib for inoperable metastatic renal cell carcinomaJ Korean Med Sci201631121983198827822939
   PubMed Web of Science ®Google Scholar
• ZhangHLShengXNLiXSSorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factorsBMC Cancer2017171162628056874
   PubMed Web of Science ®Google Scholar
• YangJSamselPANarovKCombination of everolimus with sorafenib for solid renal tumors in Tsc2 ± mice is superior to everolimus aloneNeoplasia201719211212028092822
   PubMed Web of Science ®Google Scholar
• MaXWangLLiHZPredictive immunohistochemical markers related to drug selection for patients treated with sunitinib or sorafenib for metastatic renal cell cancerSci Rep201663088627488093
   PubMed Web of Science ®Google Scholar
• ShengXNChiZHCuiCLEfficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysisOncotarget20161972704427054
   Google Scholar
• BourlonMTGaoDXTrigeroSClinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinomaCancer Med20165123386339327758076
   PubMed Web of Science ®Google Scholar
• TakahashiHNasuKMinamiMOrgan atrophy induced by sorafenib and sunitinib-quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleenPol J Radiol2016812255756527956943
   PubMedGoogle Scholar
• AfriansyahAHamidARMochtarCAUmbasRTargeted therapy for metastatic renal cell carcinomaActa Med Indones201648433534728143997
   PubMedGoogle Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• RhondaLBPatrickHPatriciaACA phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinomaClin Genitourin Cancer2014412241250
   Google Scholar
• TerakawaTMiyakeHKusudaYFujisawaMExpression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinibUrol Oncol201331449349821478036
   PubMed Web of Science ®Google Scholar
• TomasBZbynekBAlexandrPOutcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysisEur Urol201670346947526746623
   PubMed Web of Science ®Google Scholar
• ZhouYFWangSHDingTEvaluation of the effect of apatinib (YN968D1) on cytochrome P450 enzymes with cocktail probe drugs in rats by UPLC-MS/MSJ Chromatogr B Analyt Technol Biomed Life Sci2014159736875
   Web of Science ®Google Scholar
• LiJZhaoXMChenLSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer20101052920923544
   PubMed Web of Science ®Google Scholar
• PengHZhangQLiJApatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinomaOncotarget2016713172201722926967384
   PubMedGoogle Scholar
• ZhangHJApatinib for molecular targeted therapy in tumorDrug Des Devel Ther201591360756081
   Web of Science ®Google Scholar
• TianSQuanHXieCYN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivoCancer Sci201110271374138021443688
   PubMed Web of Science ®Google Scholar
• ScottAJMessersmithWAJimenoAApatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumorsDrugs Today (Barc)201551422323926020064
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
   PubMed Web of Science ®Google Scholar
• HuXZhangJXuBMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancerInt J Cancer201413581961196924604288
   PubMed Web of Science ®Google Scholar
• SongZBYuXMLouGYSalvage treatment with apatinib for advanced non-small-cell lung cancerOnco Targets Ther2017231018211825
   Web of Science ®Google Scholar